Neelima Ghanta, DO
Endocrinology, Diabetes & Metabolism · Franklin, INNPI 1710338611
Payments from drug & device makers
Across 64 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$240
- AstraZeneca$106
- Dexcom, Inc.$94
- Abbott$91
- Xeris Pharmaceuticals, Inc.$89
- Astellas Pharma US Inc$77
- plus $482 from 17 others
What the payments were for
- Food & beverage$1,179100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $240 |
| AstraZeneca | 6 | $106 |
| Dexcom, Inc. | 5 | $94 |
| Abbott | 5 | $91 |
| Xeris Pharmaceuticals, Inc. | 5 | $89 |
| Astellas Pharma US Inc | 3 | $77 |
| Kyowa Kirin, Inc. | 3 | $64 |
| Corcept Therapeutics | 2 | $47 |
| Insulet Corporation | 2 | $44 |
| Tandem Diabetes Care, Inc. | 2 | $41 |
| Novartis | 2 | $35 |
| Amgen | 2 | $31 |
| AbbVie | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Bayer | 1 | $25 |
| Zealand Pharma US, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| IBSA Pharma Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Cequr Corporation | 1 | $11 |
How this compares
$1,179 in reported general payments places this provider in the 40th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,419 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $932 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Franklin
- Carmella Evans-MolinaIndianapolis$6.3M
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Sana MeahMunster$829K
- James MaloneIndianapolis$822K
- Erica KretchmanRichmond$636K
- Emily VeenemanSeymour$583K
- Cary MariashIndianapolis$435K
- Marian KirkmanIndianapolis$371K
- Nihad MuhrezMerrillville$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.